Amylin (AMLN) Said No More Than Two Dissident Directors Elected
More News related to AMLN
- Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
- FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
- Hapoalim Securities Upgrades Amylin (AMLN) to Hold; Two Important Milestones Achieved
More News related to Corporate News
- ManTech (MANT) awarded a $286.5 million contract from the U.S. Army
- Starbucks' (SBUX) Schultz Says Via Exceeding Expectations, Company Done Closing Stores
- Highlights From DIVX's Q3 Conference Call; Licensing Business Transitioning to New Growth Categories; Guides Above for Q4 EPS
- Ambac (ABK) Slammed as 10-Q Warns of Possible Bankruptcy Protection
- Globecomm Systems (GCOM) Awarded $17.7 Million Contract
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) confirmed that no more than two of the five dissident nominees (one independent nominee from Eastbourne Capital Management, L.L.C. and one nominee from Carl Icahn) have been elected to Amylin's Board.
Additionally, Mr. Icahn's proposal to reincorporate the Company from Delaware to North Dakota has been defeated.
Related Categories
Corporate NewsStocks Mentioned
+0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
